$ARVN
Arvinas Inc Stock $arvn

$arvn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000165575924000118 Filed on July 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$102.4M	$76.50M
YoY Change	195.95%	40.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$75.80M	$31.30M
YoY Change	235.4%	21.79%
% of Gross Profit
Research & Development	$86.90M	$93.70M
YoY Change	1.16%	-9.38%
% of Gross Profit
Depreciation & Amortization	$1.100M	$1.200M
YoY Change	-8.33%	0.0%
% of Gross Profit
Operating Expenses	$162.7M	$125.0M
YoY Change	49.95%	-3.18%
Operating Profit	-$60.30M	-$48.50M
YoY Change	-18.4%	-34.99%
Interest Expense	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$11.70M	$13.50M
YoY Change	17.0%	50.0%
Pretax Income	-$48.60M	-$35.00M
YoY Change	-23.94%	-46.65%
Income Tax	$600.0K	$200.0K
% Of Pretax Income
Net Earnings	-$49.20M	-$35.20M
YoY Change	-23.13%	-47.15%
Net Earnings / Revenue	-48.05%	-46.01%
Basic Earnings Per Share	-$0.68	-$0.49
Diluted Earnings Per Share	-$0.68	-$0.49
COMMON SHARES
Basic Shares Outstanding	68.65M shares	68.43M shares
Diluted Shares Outstanding	72.10M shares	71.90M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.122B	$1.229B
YoY Change	12.33%	18.28%
Cash & Equivalents	$85.20M	$154.8M
Short-Term Investments	$1.036B	$1.074B
Other Short-Term Assets	$13.10M	$18.00M
YoY Change	-5.76%	37.4%
Inventory
Prepaid Expenses
Receivables	$7.300M	$1.800M
Other Receivables	$7.500M	$10.00M
Total Short-Term Assets	$1.150B	$1.257B
YoY Change	11.28%	18.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.800M	$9.800M
YoY Change	-46.46%	-25.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.800M	$11.60M
YoY Change	2.08%	14.85%
Total Long-Term Assets	$17.60M	$22.90M
YoY Change	-30.43%	-14.55%
TOTAL ASSETS
Total Short-Term Assets	$1.150B	$1.257B
Total Long-Term Assets	$17.60M	$22.90M
Total Assets	$1.167B	$1.280B
YoY Change	10.28%	18.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.70M	$23.20M
YoY Change	-48.4%	246.27%
Accrued Expenses	$800.0K	$52.70M
YoY Change	-98.61%	-23.62%
Deferred Revenue	$199.2M	$267.9M
YoY Change	-11.15%	16.43%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K
YoY Change	0.0%	100.0%
Total Short-Term Liabilities	$275.9M	$347.2M
YoY Change	-13.05%	13.13%
LONG-TERM LIABILITIES
Long-Term Debt	$600.0K	$700.0K
YoY Change	-25.0%	-22.22%
Other Long-Term Liabilities	$304.6M	$331.5M
YoY Change	7.63%	6.22%
Total Long-Term Liabilities	$600.0K	$700.0K
YoY Change	-25.0%	-22.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$275.9M	$347.2M
Total Long-Term Liabilities	$600.0K	$700.0K
Total Liabilities	$581.1M	$679.4M
YoY Change	-3.33%	9.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.487B	-$1.437B
YoY Change	26.2%	29.03%
Common Stock	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$586.0M	$600.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.167B	$1.280B
YoY Change	10.28%	18.1%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$49.20M	-$35.20M
YoY Change	-23.13%	-47.15%
Depreciation, Depletion And Amortization	$1.100M	$1.200M
YoY Change	-8.33%	0.0%
Cash From Operating Activities	-$128.0M	$50.30M
YoY Change	50.94%	-156.71%
INVESTING ACTIVITIES
Capital Expenditures	$700.0K	$700.0K
YoY Change	-36.36%	16.67%
Acquisitions
YoY Change
Other Investing Activities	$51.20M	$13.80M
YoY Change	-27.99%	-71.95%
Cash From Investing Activities	$50.50M	$13.10M
YoY Change	-27.86%	-73.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.400M	3.400M
YoY Change	-93.67%	580.0%
NET CHANGE
Cash From Operating Activities	-128.0M	50.30M
Cash From Investing Activities	50.50M	13.10M
Cash From Financing Activities	2.400M	3.400M
Net Change In Cash	-75.10M	66.80M
YoY Change	-425.11%	-268.69%
FREE CASH FLOW
Cash From Operating Activities	-$128.0M	$50.30M
Capital Expenditures	$700.0K	$700.0K
Free Cash Flow	-$128.7M	$49.60M
YoY Change	49.83%	-155.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71900000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71900000	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-104600000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5300000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	187200000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96100000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Additions AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions	1800000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Payments Received AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived	0	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1800000	usd
CY2023Q4	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	13100000	usd
	arvn	Accounts Payable Contract Balances Current Additions AccountsPayableContractBalancesCurrentAdditions	29200000	usd
	arvn	Accounts Payable Contract Balances Current Payments AccountsPayableContractBalancesCurrentPayments	26100000	usd
	arvn	Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements	3000000.0	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	10700000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549200000	usd
	arvn	Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements	1500000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	599200000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	191200000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	153400000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	57600000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	59800000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	200000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	200000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	700000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	800000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-700000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71700000	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-35200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-66600000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000000.0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9300000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160300000	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	10000000.0	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1256700000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1280200000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9800000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11500000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1500000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2500000	usd
CY2024Q2	arvn	Collaboration Contract Asset And Other Assets CollaborationContractAssetAndOtherAssets	11600000	usd
CY2023Q4	us-gaap	Assets Assets	1304600000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	78100000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	92200000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	267900000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	163000000.0	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1200000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1900000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	347200000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	257100000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	331300000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	386200000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	700000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	500000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	679400000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	644600000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3800000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3100000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	600200000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	660000000.0	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1279600000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1304600000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P6M
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	7200000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12500000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6500000	usd
CY2023Q4	arvn	Collaboration Contract Asset And Other Assets CollaborationContractAssetAndOtherAssets	10400000	usd
CY2024Q2	us-gaap	Assets Assets	1279600000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	800000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	200000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68600000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68600000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68000000.0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68000000.0	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1437300000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1332700000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2041200000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1995700000	usd
CY2024Q2	us-gaap	Revenues Revenues	76500000	usd
CY2023Q2	us-gaap	Revenues Revenues	54500000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93700000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103400000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31300000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25700000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	125000000.0	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	129100000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-48500000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-74600000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-100000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	13600000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000000.0	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13500000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000000.0	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35000000.0	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-65600000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300000	usd
CY2024Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1300000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-35200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-66600000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.78
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53400000	shares
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	600000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	400000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34600000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66200000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	609700000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21600000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-35200000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3500000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	600000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	600200000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	511000000.0	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18300000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-66600000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	400000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	463600000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	660000000.0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40200000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-700000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	600200000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	564900000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000000.0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	7000000.0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	463600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-104600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11200000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	7000000.0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-900000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1000000.0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	900000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1700000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1500000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	40200000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38200000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-900000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2800000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2400000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6000000.0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13100000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	3000000.0	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13900000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-600000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1000000.0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1000000.0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	50000000.0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-83100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179900000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	440400000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	492300000	usd
	arvn	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	326400000	usd
	arvn	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	638900000	usd
	arvn	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	usd
	arvn	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	42300000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	800000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1700000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	100000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114700000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	300000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	arvn	Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	5300000	usd
	arvn	Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	2000000.0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000000.0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-156900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	317200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86800000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	400000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1500000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div>The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company’s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.
CY2024Q2	arvn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	1200000000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154800000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90600000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	5500000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	5500000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160300000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96100000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000.0	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Additions AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions	1600000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Payments Received AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived	2500000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100000	usd
CY2022Q4	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	5000000.0	usd
	arvn	Accounts Payable Contract Balances Current Additions AccountsPayableContractBalancesCurrentAdditions	1700000	usd
	arvn	Accounts Payable Contract Balances Current Payments AccountsPayableContractBalancesCurrentPayments	6700000	usd
CY2024Q2	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	16200000	usd
CY2023Q2	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	9400000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	10700000	usd
	arvn	Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements	0	usd
	arvn	Capitalized Contract Cost Amortization During Period CapitalizedContractCostAmortizationDuringPeriod	1700000	usd
	arvn	Capitalized Contract Cost Amortization During Period CapitalizedContractCostAmortizationDuringPeriod	1500000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	9200000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	623700000	usd
	arvn	Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements	130000000.0	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	56300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	84600000	usd
	arvn	Contract With Customer Liability Revenue Recognized From New Collaboration ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration	23700000	usd
	arvn	Contract With Customer Liability Revenue Recognized From New Collaboration ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration	0	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	599200000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	540600000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	105000000.0	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	32200000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	599200000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33200000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32600000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23400000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21100000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9800000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11500000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
CY2021Q2	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	160000	sqft
CY2021Q2	arvn	Base Lease Rent Period BaseLeaseRentPeriod	P10Y
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000.0	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000.0	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	900000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	500000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1400000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	0	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1400000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	23200000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17800000	usd
CY2024Q2	arvn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	30700000	usd
CY2023Q4	arvn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	43100000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16000000.0	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25700000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3400000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	700000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2700000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2500000	usd
CY2024Q2	arvn	Accrued General And Administrative And Commercial Current AccruedGeneralAndAdministrativeAndCommercialCurrent	2100000	usd
CY2023Q4	arvn	Accrued General And Administrative And Commercial Current AccruedGeneralAndAdministrativeAndCommercialCurrent	2400000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	78100000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	92200000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	100000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	200000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	200000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	200000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	200000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	900000	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	0	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21600000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18300000	usd
	arvn	Share Based Compensation Arrangement By Share Based Payment Award Inducement Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants	255611	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2024Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-35200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-66600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-104600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71900000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71900000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53400000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53400000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.78
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9300000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9300000	shares
CY2024Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	5000000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001655759-24-000118-index-headers.html	Edgar Link	pending
0001655759-24-000118-index.html	Edgar Link	pending
0001655759-24-000118.txt	Edgar Link	pending
0001655759-24-000118-xbrl.zip	Edgar Link	pending
arvn-20240630.htm	Edgar Link	pending
arvn-20240630.xsd	Edgar Link	pending
arvn-20240630x10qex311.htm	Edgar Link	pending
arvn-20240630x10qex312.htm	Edgar Link	pending
arvn-20240630x10qex321.htm	Edgar Link	pending
arvn-20240630x10qex322.htm	Edgar Link	pending
exhibit101-saikemploymen.htm	Edgar Link	pending
exhibit101-saikemploymen001.jpg	Edgar Link	pending
exhibit101-saikemploymen002.jpg	Edgar Link	pending
exhibit101-saikemploymen003.jpg	Edgar Link	pending
exhibit101-saikemploymen004.jpg	Edgar Link	pending
exhibit101-saikemploymen005.jpg	Edgar Link	pending
exhibit101-saikemploymen006.jpg	Edgar Link	pending
exhibit101-saikemploymen007.jpg	Edgar Link	pending
exhibit101-saikemploymen008.jpg	Edgar Link	pending
exhibit101-saikemploymen009.jpg	Edgar Link	pending
exhibit101-saikemploymen010.jpg	Edgar Link	pending
exhibit101-saikemploymen011.jpg	Edgar Link	pending
exhibit101-saikemploymen012.jpg	Edgar Link	pending
exhibit101-saikemploymen013.jpg	Edgar Link	pending
exhibit102-cacacepromoti.htm	Edgar Link	pending
exhibit102-cacacepromoti001.jpg	Edgar Link	pending
exhibit104-novartisxarvi.htm	Edgar Link	pending
exhibit104-novartisxarvi001.jpg	Edgar Link	pending
exhibit104-novartisxarvi002.jpg	Edgar Link	pending
exhibit104-novartisxarvi003.jpg	Edgar Link	pending
exhibit104-novartisxarvi004.jpg	Edgar Link	pending
exhibit104-novartisxarvi005.jpg	Edgar Link	pending
exhibit104-novartisxarvi006.jpg	Edgar Link	pending
exhibit104-novartisxarvi007.jpg	Edgar Link	pending
exhibit104-novartisxarvi008.jpg	Edgar Link	pending
exhibit104-novartisxarvi009.jpg	Edgar Link	pending
exhibit104-novartisxarvi010.jpg	Edgar Link	pending
exhibit104-novartisxarvi011.jpg	Edgar Link	pending
exhibit104-novartisxarvi012.jpg	Edgar Link	pending
exhibit104-novartisxarvi013.jpg	Edgar Link	pending
arvn-20240630_def.xml	Edgar Link	unprocessable
arvn-20240630_lab.xml	Edgar Link	unprocessable
arvn-20240630_htm.xml	Edgar Link	completed
arvn-20240630_pre.xml	Edgar Link	unprocessable
exhibit104-novartisxarvi014.jpg	Edgar Link	pending
exhibit104-novartisxarvi015.jpg	Edgar Link	pending
exhibit104-novartisxarvi016.jpg	Edgar Link	pending
exhibit104-novartisxarvi017.jpg	Edgar Link	pending
exhibit104-novartisxarvi018.jpg	Edgar Link	pending
exhibit104-novartisxarvi019.jpg	Edgar Link	pending
exhibit104-novartisxarvi020.jpg	Edgar Link	pending
exhibit104-novartisxarvi021.jpg	Edgar Link	pending
exhibit104-novartisxarvi022.jpg	Edgar Link	pending
exhibit104-novartisxarvi023.jpg	Edgar Link	pending
exhibit104-novartisxarvi024.jpg	Edgar Link	pending
exhibit104-novartisxarvi025.jpg	Edgar Link	pending
exhibit104-novartisxarvi026.jpg	Edgar Link	pending
exhibit104-novartisxarvi027.jpg	Edgar Link	pending
exhibit104-novartisxarvi028.jpg	Edgar Link	pending
exhibit104-novartisxarvi029.jpg	Edgar Link	pending
exhibit104-novartisxarvi030.jpg	Edgar Link	pending
exhibit104-novartisxarvi031.jpg	Edgar Link	pending
exhibit104-novartisxarvi032.jpg	Edgar Link	pending
exhibit104-novartisxarvi033.jpg	Edgar Link	pending
exhibit104-novartisxarvi034.jpg	Edgar Link	pending
exhibit104-novartisxarvi035.jpg	Edgar Link	pending
exhibit104-novartisxarvi036.jpg	Edgar Link	pending
exhibit104-novartisxarvi037.jpg	Edgar Link	pending
exhibit104-novartisxarvi038.jpg	Edgar Link	pending
exhibit104-novartisxarvi039.jpg	Edgar Link	pending
exhibit104-novartisxarvi040.jpg	Edgar Link	pending
exhibit104-novartisxarvi041.jpg	Edgar Link	pending
exhibit104-novartisxarvi042.jpg	Edgar Link	pending
exhibit104-novartisxarvi043.jpg	Edgar Link	pending
exhibit104-novartisxarvi044.jpg	Edgar Link	pending
exhibit104-novartisxarvi045.jpg	Edgar Link	pending
exhibit104-novartisxarvi046.jpg	Edgar Link	pending
exhibit104-novartisxarvi047.jpg	Edgar Link	pending
exhibit104-novartisxarvi048.jpg	Edgar Link	pending
exhibit104-novartisxarvi049.jpg	Edgar Link	pending
exhibit104-novartisxarvi050.jpg	Edgar Link	pending
exhibit104-novartisxarvi051.jpg	Edgar Link	pending
exhibit104-novartisxarvi052.jpg	Edgar Link	pending
exhibit104-novartisxarvi053.jpg	Edgar Link	pending
exhibit104-novartisxarvi054.jpg	Edgar Link	pending
exhibit104-novartisxarvi055.jpg	Edgar Link	pending
exhibit104-novartisxarvi056.jpg	Edgar Link	pending
exhibit104-novartisxarvi057.jpg	Edgar Link	pending
exhibit104-novartisxarvi058.jpg	Edgar Link	pending
exhibit104-novartisxarvi059.jpg	Edgar Link	pending
exhibit104-novartisxarvi060.jpg	Edgar Link	pending
exhibit104-novartisxarvi061.jpg	Edgar Link	pending
exhibit104-novartisxarvi062.jpg	Edgar Link	pending
exhibit104-novartisxarvi063.jpg	Edgar Link	pending
exhibit104-novartisxarvi064.jpg	Edgar Link	pending
exhibit104-novartisxarvi065.jpg	Edgar Link	pending
exhibit104-novartisxarvi066.jpg	Edgar Link	pending
exhibit104-novartisxarvi067.jpg	Edgar Link	pending
exhibit104-novartisxarvi068.jpg	Edgar Link	pending
exhibit104-novartisxarvi069.jpg	Edgar Link	pending
exhibit104-novartisxarvi070.jpg	Edgar Link	pending
exhibit104-novartisxarvi071.jpg	Edgar Link	pending
exhibit104-novartisxarvi072.jpg	Edgar Link	pending
exhibit104-novartisxarvi073.jpg	Edgar Link	pending
exhibit104-novartisxarvi074.jpg	Edgar Link	pending
exhibit104-novartisxarvi075.jpg	Edgar Link	pending
exhibit104-novartisxarvi076.jpg	Edgar Link	pending
exhibit104-novartisxarvi077.jpg	Edgar Link	pending
exhibit104-novartisxarvi078.jpg	Edgar Link	pending
exhibit104-novartisxarvi079.jpg	Edgar Link	pending
exhibit104-novartisxarvi080.jpg	Edgar Link	pending
exhibit105-novartisxarvi.htm	Edgar Link	pending
exhibit105-novartisxarvi001.jpg	Edgar Link	pending
exhibit105-novartisxarvi002.jpg	Edgar Link	pending
exhibit105-novartisxarvi003.jpg	Edgar Link	pending
exhibit105-novartisxarvi004.jpg	Edgar Link	pending
exhibit105-novartisxarvi005.jpg	Edgar Link	pending
exhibit105-novartisxarvi006.jpg	Edgar Link	pending
exhibit105-novartisxarvi007.jpg	Edgar Link	pending
exhibit105-novartisxarvi008.jpg	Edgar Link	pending
exhibit105-novartisxarvi009.jpg	Edgar Link	pending
exhibit105-novartisxarvi010.jpg	Edgar Link	pending
exhibit105-novartisxarvi011.jpg	Edgar Link	pending
exhibit105-novartisxarvi012.jpg	Edgar Link	pending
exhibit105-novartisxarvi013.jpg	Edgar Link	pending
exhibit105-novartisxarvi014.jpg	Edgar Link	pending
exhibit105-novartisxarvi015.jpg	Edgar Link	pending
exhibit105-novartisxarvi016.jpg	Edgar Link	pending
exhibit105-novartisxarvi017.jpg	Edgar Link	pending
exhibit105-novartisxarvi018.jpg	Edgar Link	pending
exhibit105-novartisxarvi019.jpg	Edgar Link	pending
exhibit105-novartisxarvi020.jpg	Edgar Link	pending
exhibit106-amendedyaleag.htm	Edgar Link	pending
exhibit106-amendedyaleag001.jpg	Edgar Link	pending
exhibit106-amendedyaleag002.jpg	Edgar Link	pending
exhibit106-amendedyaleag003.jpg	Edgar Link	pending
exhibit106-amendedyaleag004.jpg	Edgar Link	pending
exhibit106-amendedyaleag005.jpg	Edgar Link	pending
exhibit106-amendedyaleag006.jpg	Edgar Link	pending
exhibit106-amendedyaleag007.jpg	Edgar Link	pending
exhibit106-amendedyaleag008.jpg	Edgar Link	pending
exhibit106-amendedyaleag009.jpg	Edgar Link	pending
exhibit106-amendedyaleag010.jpg	Edgar Link	pending
exhibit106-amendedyaleag011.jpg	Edgar Link	pending
exhibit106-amendedyaleag012.jpg	Edgar Link	pending
exhibit106-amendedyaleag013.jpg	Edgar Link	pending
exhibit106-amendedyaleag014.jpg	Edgar Link	pending
exhibit106-amendedyaleag015.jpg	Edgar Link	pending
exhibit106-amendedyaleag016.jpg	Edgar Link	pending
exhibit106-amendedyaleag017.jpg	Edgar Link	pending
exhibit106-amendedyaleag018.jpg	Edgar Link	pending
exhibit106-amendedyaleag019.jpg	Edgar Link	pending
exhibit106-amendedyaleag020.jpg	Edgar Link	pending
exhibit106-amendedyaleag021.jpg	Edgar Link	pending
exhibit106-amendedyaleag022.jpg	Edgar Link	pending
exhibit106-amendedyaleag023.jpg	Edgar Link	pending
exhibit106-amendedyaleag024.jpg	Edgar Link	pending
exhibit106-amendedyaleag025.jpg	Edgar Link	pending
exhibit106-amendedyaleag026.jpg	Edgar Link	pending
exhibit106-amendedyaleag027.jpg	Edgar Link	pending
exhibit106-amendedyaleag028.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
arvn-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARVN
Arvinas Inc Stock $arvn

2024 Q3 Form 10-Q Financial Statement

#000165575924000118 Filed on July 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARVN Arvinas Inc Stock $arvn

2024 Q3 Form 10-Q Financial Statement

#000165575924000118 Filed on July 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARVN
Arvinas Inc Stock $arvn